Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FS120 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- F-star
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FS120 + pembrolizumab is a combination investigational regimen consisting of FS120, a first-in-class tetravalent bispecific antibody that acts as a dual-agonist targeting OX40 and CD137 (also known as 4-1BB), together with pembrolizumab, a programmed death-1 (PD-1)-blocking monoclonal antibody immunotherapy. FS120 binds OX40 and CD137 to stimulate CD4+ and CD8+ T cell activation and proliferation while minimizing hepatotoxicity compared to previous CD137-targeting agents. Pembrolizumab inhibits the interaction between PD-1 and its ligands, resulting in enhanced anti-tumor immune responses. The combination is being studied for synergistic immune activation in oncology, specifically advanced malignancies. FS120 is being developed by F-star Therapeutics; pembrolizumab (Keytruda) is developed and manufactured by Merck.
- Other names
- FS120 + KeytrudaFS120 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TNFRSF9 (CD137 extracellular domain)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on FS120 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FS120 + pembrolizumab.